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We have analysed samples for RFLPs from 154 people including 53 women at risk of being DMD carriers from 37 families. We used the probes pERT87.8 (BstXI and TaqI polymorphisms), 87-15 (TaqI polymorphism), and pXJ1.1 (TaqI polymorphism). Forty-one of the women have had their risks altered. We found one deletion (pERT87-8) out of 23 DNA samples analysed from affected boys. We used a recombination fraction of 005 in risk calculations but did not detect any known crossovers. In nine of the families there is only an isolated case of DMD. In families where we have not been able to alter the risk of the women being a carrier (for example, because all brothers are dead), we have offered prenatal exclusion and have carried out one first trimester prenatal diagnosis on this basis. Lowering the risk of an affected fetus to <2.5% appears to be a satisfactory situation for many (most) of the women involved and seems to justify the introduction of genetic prediction based on single intragenic probes despite the 5%/0 recombination frequency.
Polymorphic DNA segments linked to DMD were reported some years ago' and these served to confirm the localisation of the DMD locus to Xp2l.
Recently two different but more direct approaches have been used to isolate the region of the X chromosome carrying the gene. One approach produced clones of sequences deleted in a boy with DMD and a visible chromosomal deletion of the region Xp2l.2 These clones, the pERT series, show several high frequency polymorphisms. (CVS) followed by early termination of all male fetuses.
We have found that DNA analysis can improve this situation (that is, lessen the risk of normal males being terminated) particularly by using prenatal exclusion.
In these women the DNA was analysed to find a probe RFLP for which they were heterozygous and where either their mother was homozygous or DNA was available from both parents. In this situation all of the consultand's risk is carried on the allele she has inherited from her mother (provided the consultand has an affected relative other than her own son). Considering the possibility of a recombination at meiosis, a male fetus inheriting her paternal RFLP allele has a low risk of being affected (recombination fraction x her carrier risk) and the risk of a male fetus carrying her maternal RFLP allele being affected approaches her own risk of being a carrier.
Where the consultand's risk of being a carrier is 20% or less a male offspring carrying her paternal allele has a 1% or less risk of being affected. Where the consultand's carrier risk is between 20% and 100% the risk of a male fetus who receives the paternal allele being affected ranges from 1% to 5%.
This approach has been useful in a number of different clinical situations.
Example I (fig 2)
The simplest situation is demonstrated by the following family. The pregnant consultand was referred for clarification of her carrier status. Her mother was homozygous for the pERT probe polymorphisms. Her risk of being a carrier based on pedigree and CK data was 7-6%. A male fetus inheriting the 2-2 kb band had a 0-3% probability of having DMD but a male fetus with the 4-2 kb band had a 7-3% probability of having the disease. The consultand had planned to have fetal sexing and termination of males, but given this option asked us to test not only the sex of the fetus but also its RFLP 
Example 3 (fig 4)
In the family illustrated in fig 4 , the consultand's father was unavailable. She and her mother were heterozygous for both the BstXI and the TaqI polymorphisms of pERT87-8. Although phase in the mother was known with considerable certainty from her two normal sons, in this particular situation, where both mother and daughter are heterozygous, it is impossible to tell which of the mother's chromosomes has been inherited by the daughter in the absence of the father. Therefore, her risk could not be clarified. Using the TaqI polymorphism of XJ1-1, however, her mother was homozygous and she was heterozygous and so prenatal exclusion could be offered.
The same situation has arisen in the case of a girl who was adopted where we were able to obtain a sample of blood for DNA extraction from her mother but not from her father. Sporadic cases Twelve of the 53 consultands investigated have been from families with a sporadic case of Duchenne muscular dystrophy and where the mother's creatine kinase fell within the normal range. In 11 of these cases the girl inherited the opposite RFLP allele from her affected brother, lowering her risk considerably. One consultand received the same RFLP allele as her affected brother, raising her carrier risk from 4% to 8%. She has opted to have prenatal exclusion if she becomes pregnant.
Discussion
We have reported our experience of using a limited number of DNA probes for genetic prediction in DMD families for the period August 1985 to May 1986. Our department does not have a research programme on the linkage relationship of the many sequences around Xp2l and these analyses were introduced purely as a clinical service. As such they represent what can be achieved using the simplest strategy of gene tracking with single, closely linked probes, the probabilities being calculated on the reported pooled recombination frequency observed in DMD families.
We selected the pERT87 probes initially, and later added the XJ1.1 probe because deletion and linkage data suggested that these were closest to the DMD mutation25 and the strategies used to clone these sequences were likely to yield gene specific clones. The recent isolation of a sequence from within the pERT87 locus that hybridises to a large mRNA transcript from human fetal muscle supports this view. 8 While we were early proponents of the use of loosely linked flanking DNA markers in DMD families for genetic prediction,'2 by August 1985 the situation was confused. There was evidence of nonoverlapping deletions associated with the DMD mutation in different families6 and a significant number of recombinations between the DMD mutation and the pERT probes,3 observations that suggested that the DMD locus was very large and possibly a recombination hot spot. Predictions based on loosely linked flanking probes assume that gene conversion or localised double crossover events within the DMD locus would be rare, an assumption that we felt could not be made until more was known about the locus. While no recombination between flanking probes must increase the reliability of the prediction, it is still not certain by how much. If a recombination with a flanking probe is found, then no prediction would be made on the grounds that the recombination may have occurred between the pERT or XJ1 1 locus and the DMD mutation. About 15% of cases would be expected to fall into this category and Bakker et al, 13 in perhaps the largest systematic series using flanking markers to date, found a comparable figure. They reported that 17 of 136 (12-5%) women could be given no conclusive statement on carrier risk because of a detected recombination between the nearest informative bridging markers. While believing that the use of single linked probes is only a passing phase in genetic prediction in DMD families, the series reported here nevertheless indicates that this approach can be extremely useful in clarifying carrier status.
In eight cases we have found that we have used one probe to determine a consultand's carrier status but she has been homozygous for that probe and has a carrier risk of >2-5%. In all these cases the consultand has been heterozygous for another probe which could be used for prenatal exclusion if necessary. This shows that one often has to investigate the family for several polymorphisms in order to offer a service.
Twelve women were shown to have risks of >90% of being DMD carriers. They could be offered first trimester prenatal diagnosis but there would still be a 5%YO risk of an 'unaffected' male being affected which might be unacceptable to the family. In the only such pregnancy analysed by us, the woman decided eventually against any form of prenatal diagnosis and sadly has had an affected son.
In the group of women whose prior risk fell between 20% and 49% the women fell into three groups. (1) In five cases the risk could not be altered with the probes used. Three of these women have subsequently become pregnant and requested prenatal exclusion. (2) In 10 cases the risk was lowered to <6-3%. Three of these women cancelled prenatal tests for fetal sexing already arranged. (3) In the other four cases the risk was substantially raised. None of these women has so far become pregnant.
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